PMDA drug package insert
アンブリセンタン錠2.5mg「KMP」
PMDA Prescription drug · 共創未来ファーマ株式会社 · package insert Aug 29, 2024
Key facts
| Brand names | アンブリセンタン錠2.5mg「KMP」 |
|---|---|
| Nonproprietary names | アンブリセンタン |
| Companies | 製造販売元／共創未来ファーマ株式会社, 販売元／株式会社 三和化学研究所 |
| Product type | Prescription drug |
| Therapeutic category | エンドセリン受容体拮抗薬 |
| Therapeutic category codes | 87219 |
| YJ codes | 2190031F1031 |
| Approval numbers | 30300AMX00361000 |
| Package insert edition | 第2版 |
| Package insert date | Aug 29, 2024 |
| PMDA document key | 300166_2190031F1031_2 |
| PMDA company code | 300166 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: